<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=29699"><dc:title>Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery</dc:title><dc:creator>Jurca,	Tomaž	(Avtor)
	</dc:creator><dc:creator>Boltežar,	Lučka	(Avtor)
	</dc:creator><dc:creator>Oražem,	Miha	(Avtor)
	</dc:creator><dc:creator>Fujs Komloš,	Kristina	(Avtor)
	</dc:creator><dc:creator>Pohar,	Katka	(Avtor)
	</dc:creator><dc:creator>Jevnikar,	Sara	(Avtor)
	</dc:creator><dc:creator>Poljak,	Mario	(Avtor)
	</dc:creator><dc:creator>Mlakar-Mastnak,	Denis	(Avtor)
	</dc:creator><dc:creator>Rotovnik-Kozjek,	Nada	(Avtor)
	</dc:creator><dc:creator>Vratanar,	Bor	(Avtor)
	</dc:creator><dc:creator>Ocvirk,	Janja	(Avtor)
	</dc:creator><dc:creator>Ihan,	Alojz	(Avtor)
	</dc:creator><dc:subject>lymphoma</dc:subject><dc:subject>B-cell</dc:subject><dc:subject>rituximab</dc:subject><dc:subject>COVID-19 vaccines</dc:subject><dc:description>Rituximab-treated patients with B-cell lymphoma exhibit profound B-cell depletion and impaired vaccine-induced antibody responses. However, it remains uncertain whether recovery of peripheral B-cell counts after rituximab is sufficient to restore effective humoral immunity following booster vaccination. Patients and methods In this prospective, single-center observational study at the Institute of Oncology Ljubljana, adult B-cell lymphoma patients treated with or previously exposed to rituximab received the Comirnaty® mRNA COVID-19 vaccine. Antibody responses to the SARS-CoV-2 spike and nucleoprotein were measured at baseline, 14 days after the second dose, and at 3, 6, 9, and 12 months. A third dose was administered at 6 months. T-cell responses (IFN-γ release) were assessed in patients before and after the primary series and booster dose. Lymphocyte subsets were analysed pre-vaccination. Adverse events and nutritional status were monitored. Results Patients undergoing anti-CD20 therapy showed absent antibody responses. Longer intervals since rituximab correlated with peripheral B-cell repopulation. However, even after reaching normal B-cell counts, patients’ antibody responses after revaccination remained significantly lower than in controls. Conclusions Rituximab is associated with impaired vaccine-induced antibody responses. Despite recovery of peripheral B-cell counts, patients with B-cell lymphoma show reduced humoral responses compared with healthy individuals following booster COVID-19 vaccination.</dc:description><dc:publisher>Association of Radiology and Oncology</dc:publisher><dc:date>2026</dc:date><dc:date>2026-06-03 11:59:43</dc:date><dc:type>Neznano</dc:type><dc:identifier>29699</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language><dc:rights>by Authors</dc:rights></rdf:Description></rdf:RDF>
